Q3 2025 · 13F-HR
Sofinnova Investments, Inc.holdings as filed
Filed 2025-11-14 · accession 0001104659-25-111551
$1.83B
Reported value
62
Positions
2025-09-30
Period end
The Brief · Sofinnova Investments, Inc. · Q3 2025
AI · grounded in 13F
Sofinnova Investments, Inc. established a new position in Natera Inc NTRA valued at $249.5M. The fund also initiated new stakes in Gilead Sciences Inc GILD for $139M and United Therapeutics Corp UTHR for $120.6M. Other new additions include Vera Therapeutics Inc VERA and Jazz Pharmaceuticals PLC JAZZ. The fund ended the period with 59 positions and total AUM of $1.8B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | Natera Inc | $249.5M | 13.6% | 1,550,280 | Common | SOLE |
| 375558103 | GILD | Gilead Sciences Inc | $139.0M | 7.60% | 1,252,312 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $81.2M | 4.44% | 2,793,987 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp | $79.9M | 4.37% | 190,626 | Common | SOLE |
| G50871105 | JAZZ | Jazz Pharmaceuticals PLC | $77.6M | 4.24% | 588,828 | Common | SOLE |
| 046353108 | AZNN | AstraZeneca PLC | $63.2M | 3.46% | 823,933 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics Inc | $57.8M | 3.16% | 1,947,579 | Common | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $55.6M | 3.04% | 569,427 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $52.5M | 2.87% | 779,616 | Common | SOLE |
| 46120E602 | ISRG | Intuitive Surgical Inc | $49.6M | 2.71% | 110,896 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $47.8M | 2.61% | 393,499 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd | $47.6M | 2.61% | 3,149,270 | Common | SOLE |
| 464287556 | IBB | iShares TR | $46.9M | 2.57% | 325,000 | PUT | SOLE |
| 92532F100 | VRTX | Vertex Pharmaceuticals Inc | $46.2M | 2.52% | 117,875 | Common | SOLE |
| 10806X102 | BBIO | BridgeBio Pharma Inc | $43.2M | 2.36% | 831,847 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp | $40.7M | 2.23% | 97,100 | PUT | SOLE |
| 78464A870 | XBI | SPDR Series Trust | $40.1M | 2.19% | 400,000 | PUT | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $38.2M | 2.09% | 875,925 | Common | SOLE |
| 00287Y109 | ABBV | AbbVie Inc | $35.0M | 1.91% | 150,966 | Common | SOLE |
| 04272N102 | AVBP | Arrivent BioPharma Inc | $31.3M | 1.71% | 1,696,752 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $30.6M | 1.67% | 2,127,941 | Common | SOLE |
| N90064101 | QURE | Uniqure NV | $29.2M | 1.60% | 500,000 | PUT | SOLE |
| 377322102 | GKOS | Glaukos Corp | $25.5M | 1.40% | 312,994 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences Inc | $25.1M | 1.37% | 922,695 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals Inc | $24.9M | 1.36% | 246,966 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $22.5M | 1.23% | 473,625 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $22.5M | 1.23% | 565,417 | Common | SOLE |
| 30063P105 | EXK | Exact Sciences Corp | $20.0M | 1.09% | 365,000 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V | $19.0M | 1.04% | 2,227,837 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc | $18.6M | 1.02% | 900,000 | CALL | SOLE |
| N69605108 | PHVS | Pharvaris N V | $18.5M | 1.01% | 739,876 | Common | SOLE |
| 868459108 | SUPN | Supernus Pharmaceuticals Inc | $18.0M | 0.99% | 377,066 | Common | SOLE |
| N90064101 | QURE | Uniqure NV | $17.5M | 0.96% | 300,000 | CALL | SOLE |
| 03969F109 | RCUS | Arcus Biosciences Inc | $16.6M | 0.91% | 1,222,263 | Common | SOLE |
| N5749R100 | 2GH | Merus N V | $15.7M | 0.86% | 166,729 | Common | SOLE |
| 457669307 | INSM | Insmed Inc | $15.0M | 0.82% | 104,339 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences Inc | $14.8M | 0.81% | 440,092 | Common | SOLE |
| 09077V100 | BIOA | BioAge Labs Inc | $13.5M | 0.74% | 2,293,788 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $12.5M | 0.68% | 253,375 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $12.5M | 0.68% | 985,828 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $11.5M | 0.63% | 186,932 | Common | SOLE |
| 36266G107 | GEHC | GE Healthcare Technologies Inc | $11.3M | 0.62% | 151,085 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $11.2M | 0.61% | 166,281 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines Inc | $9.2M | 0.50% | 172,833 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $8.7M | 0.47% | 2,427,724 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $8.4M | 0.46% | 520,240 | Common | SOLE |
| N90064101 | QURE | Uniqure NV | $8.0M | 0.44% | 136,862 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio Inc | $7.8M | 0.43% | 254,268 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $7.1M | 0.39% | 2,028,886 | Common | SOLE |
| 640268306 | NKTR | Nektar Therapeutics | $6.7M | 0.37% | 118,419 | Common | SOLE |
| 53635D202 | LQDA | Liquidia Corporation | $5.7M | 0.31% | 250,000 | PUT | SOLE |
| 171757206 | CDTX | Cidara Therapeutics Inc | $5.2M | 0.28% | 54,197 | Common | SOLE |
| 45257U108 | IMNM | Immunome Inc | $5.1M | 0.28% | 436,051 | Common | SOLE |
| 65343E207 | NXTC | Nextcure Inc | $1.3M | 0.07% | 222,654 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd | $1.3M | 0.07% | 170,943 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Hldg Corp | $1.2M | 0.06% | 31,410 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences Inc | $926,784 | 0.05% | 107,391 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $895,582 | 0.05% | 13,553 | Common | SOLE |
| 097702203 | BOLT | Bolt Biotherapeutics Inc | $732,676 | 0.04% | 137,721 | Common | SOLE |
| 004225108 | ACAD | Acadia Pharmaceuticals Inc | $571,912 | 0.03% | 26,800 | Common | SOLE |
| G31249108 | ESTA | Establishment Labs Hldgs Inc | $442,159 | 0.02% | 10,787 | Common | SOLE |
| 45175G207 | IMA | ImageneBio Inc | $259,855 | 0.01% | 31,884 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.